Assessing Tyra Biosciences (TYRA) Valuation After Strong One Year Share Price Performance

Simply Wall St.

Mar 23

AdvertisementRecent stock performance and what it might signal Tyra Biosciences (TYRA) has drawn attention after a 2.7% decline in the last session, following a sharp move over the past 3 months that ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2621872752"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2621872752\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2621872752?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-03-23 13:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621872752","market":"nz","top_or_hot":-1,"title":"Assessing Tyra Biosciences (TYRA) Valuation After Strong One Year Share Price Performance","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementRecent stock performance and what it might signal Tyra Biosciences (TYRA) has drawn attention after a 2.7% decline in the last session, following a sharp move over the past 3 months that ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tyra/tyra-biosciences/news/assessing-tyra-biosciences-tyra-valuation-after-strong-one-y\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assessing Tyra Biosciences (TYRA) Valuation After Strong One Year Share Price Performance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssessing Tyra Biosciences (TYRA) Valuation After Strong One Year Share Price Performance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-23 13:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tyra/tyra-biosciences/news/assessing-tyra-biosciences-tyra-valuation-after-strong-one-y><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementRecent stock performance and what it might signal Tyra Biosciences (TYRA) has drawn attention after a 2.7% decline in the last session, following a sharp move over the past 3 months that ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tyra/tyra-biosciences/news/assessing-tyra-biosciences-tyra-valuation-after-strong-one-y\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tyra/tyra-biosciences/news/assessing-tyra-biosciences-tyra-valuation-after-strong-one-y","article_id":"2621872752","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tyra/tyra-biosciences/news/assessing-tyra-biosciences-tyra-valuation-after-strong-one-y","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2621872752","pubTimestamp":1774242316,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Recent stock performance and what it might signal\nTyra Biosciences (TYRA) has drawn attention after a 2.7% decline in the last session, following a sharp move over the past 3 months that left the stock up 46.4%.\nOver the past month the shares are up 17.6%, while the 1 year total return stands at 247.5%, set against a recent closing price of US$37.15 and a market value of about US$2.0b.\nSee our latest analysis for Tyra Biosciences.\nPut simply, Tyra Biosciences has combined sharp short term...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","TYRA":"Tyra Biosciences, Inc."},"translate_title":"在一年强劲的股价表现后评估Tyra Biosciences(TYRA)的估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TYRA":1.5},"content_text":"AdvertisementRecent stock performance and what it might signal Tyra Biosciences (TYRA) has drawn attention after a 2.7% decline in the last session, following a sharp move over the past 3 months that left the stock up 46.4%. Over the past month the shares are up 17.6%, while the 1 year total return stands at 247.5%, set against a recent closing price of US$37.15 and a market value of about US$2.0b. See our latest analysis for Tyra Biosciences. Put simply, Tyra Biosciences has combined sharp short term share price momentum with very strong 1 year total shareholder returns. This suggests investors are reassessing both its growth potential and risk profile. If you are looking for other potential growth stories in a similar space, this is a good moment to scan the wider healthcare AI opportunity set via 36 healthcare AI stocks With Tyra now at US$37.15 and no current revenue, yet sitting about 33% below the average analyst price target of US$49.51, it is reasonable to ask whether there is still a buying opportunity here or whether future growth is already priced in. Preferred Price to Book Ratio of 7.7x: Is it justified? Tyra Biosciences currently trades at a P/B of 7.7x, which stands well above both the US Biotechs industry average and the closer peer group average. P/B compares the share price to the company’s book value per share. A higher P/B typically reflects stronger expectations for future value creation relative to the current balance sheet. At 7.7x, Tyra’s P/B is more than three times the broader US Biotechs industry average of 2.5x and roughly double the peer average of 3.9x. This points to a materially richer valuation than many comparable names. See what the numbers say about this price — find out in our valuation breakdown. Result: Price-to-book of 7.7x (OVERVALUED) However, you also have to weigh clinical trial uncertainty and the current lack of revenue, as any setback in these areas could quickly challenge such a rich valuation. Find out about the key risks to this Tyra Biosciences narrative. Next Steps The mix of strong recent returns and a rich P/B multiple can feel exciting and uncomfortable at the same time, so move quickly, review the underlying data, and weigh both sides of the story by checking the 1 key reward and 2 important warning signs Looking for more investment ideas? If you stop with just one stock, you could miss opportunities that fit your style even better. Take a moment to scan a few focused shortlists.  Target resilient compounding potential by checking companies screened for stability and income through the 13 dividend fortresses. Focus on quality at a reasonable entry point by reviewing the 54 high quality undervalued stocks. Identify potential future standouts early by scanning the screener containing 26 high quality undiscovered gems.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Tyra Biosciences might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}